Free Trial

Bright Minds Biosciences (DRUG) News Today

Bright Minds Biosciences logo
$32.46 +0.47 (+1.47%)
As of 05/20/2025 04:00 PM Eastern

DRUG Latest News

Bright Minds Biosciences Inc. stock logo
Janus Henderson Group PLC Buys New Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)
Janus Henderson Group PLC bought a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 508,776 shares of the company's stock, valued at approximately $18,392,000. Janus Henderson Group PLC o
FY2025 Earnings Forecast for DRUG Issued By Chardan Capital
Bright Minds Biosciences Inc. stock logo
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded to Strong-Buy at Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of Bright Minds Biosciences to a "strong-buy" rating in a report on Tuesday.
Bright Minds Biosciences Inc. stock logo
Bright Minds Biosciences (DRUG) to Release Earnings on Wednesday
Bright Minds Biosciences (NASDAQ:DRUG) will be releasing earnings before the market opens on Wednesday, May 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-21-bright-minds-biosciences-inc-stock/)
Bright Minds Biosciences Inc. stock logo
TD Cowen Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG)
TD Cowen initiated coverage on shares of Bright Minds Biosciences in a research report on Tuesday. They issued a "buy" rating on the stock.
Bright Minds Biosciences Inc. stock logo
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of "Buy" from Brokerages
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommen
Bright Minds Biosciences Inc. stock logo
Chardan Capital Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG)
Chardan Capital assumed coverage on shares of Bright Minds Biosciences in a research report on Wednesday. They set a "buy" rating and a $80.00 price target on the stock.
Bright Minds Biosciences Inc. stock logo
Schonfeld Strategic Advisors LLC Takes Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)
Schonfeld Strategic Advisors LLC purchased a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 69,812 sha
Bright Minds Biosciences Inc. stock logo
Acuta Capital Partners LLC Takes Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)
Acuta Capital Partners LLC acquired a new position in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 69,124 shares of the company's stock, valued at
Bright Minds Biosciences Inc. stock logo
460,829 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Purchased by RA Capital Management L.P.
RA Capital Management L.P. acquired a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 460,829 shares of the compa
Bright Minds Biosciences Inc. stock logo
AdvisorShares Investments LLC Sells 179,345 Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG)
AdvisorShares Investments LLC decreased its position in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) by 98.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,075 shares of the company's stock
Bright Minds Biosciences Inc. stock logo
44,580 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Purchased by Boothbay Fund Management LLC
Boothbay Fund Management LLC acquired a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 44,580 shares of the company's stock, valued at approximately $1,606,000. Boothbay Fu
Bright Minds Biosciences Inc. stock logo
Adage Capital Partners GP L.L.C. Acquires New Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)
Adage Capital Partners GP L.L.C. bought a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 132,500 shares of the company's stock, valued at approximate
Bright Minds Biosciences Inc. stock logo
Vivo Capital LLC Invests $9.06 Million in Bright Minds Biosciences Inc. (NASDAQ:DRUG)
Vivo Capital LLC acquired a new stake in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 251,572 shares of the company's stock, valued at approximately $9,06
Bright Minds Biosciences Inc. stock logo
Walleye Capital LLC Acquires New Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG)
Walleye Capital LLC bought a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 103,192 shares of the company's stock,
Bright Minds Biosciences Inc. stock logo
Springhill Fund Asset Management HK Co Ltd Purchases Shares of 60,648 Bright Minds Biosciences Inc. (NASDAQ:DRUG)
Springhill Fund Asset Management HK Co Ltd acquired a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 60,648 shares of the company'
Bright Minds Biosciences Inc. stock logo
Atika Capital Management LLC Takes Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)
Atika Capital Management LLC bought a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 15,000 shares of the company's stock, valued at
Bright Minds Biosciences Inc. stock logo
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Short Interest Update
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 107,700 shares, a decline of 14.8% from the February 13th total of 126,400 shares. Approximately 2.2% of the company's stock are sold short. Based on an average trading volume of 79,700 shares, the days-to-cover ratio is currently 1.4 days.
Bright Minds Biosciences Inc. stock logo
Cantor Fitzgerald Has Weak Forecast for DRUG FY2025 Earnings
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Bright Minds Biosciences in a research report issued to clients and investors on Thursday, March 13th. Cantor Fitzgerald analyst C. Duncan now expects t
Bright Minds Biosciences Inc. stock logo
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 0.8% - Here's Why
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 0.8% - Here's What Happened
Bright Minds Biosciences expands Scientific Advisory Board
Bright Minds Biosciences Inc. stock logo
HC Wainwright Issues Pessimistic Estimate for DRUG Earnings
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for Bright Minds Biosciences in a research note issued to investors on Wednesday, February 19th. HC Wainwright analyst P. Trucchio now forecast
Bright Minds Biosciences Inc. stock logo
Bright Minds Biosciences' (DRUG) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and set a $85.00 price objective on shares of Bright Minds Biosciences in a research report on Wednesday.
Bright Minds Biosciences (DRUG) Receives a New Rating from Piper Sandler
Bright Minds Biosciences Inc. stock logo
Bright Minds Biosciences (NASDAQ:DRUG) Announces Earnings Results, Beats Estimates By $0.24 EPS
Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.24.
Vascular health doctor in clinical laboratory for medical research and development concepts. and science with a microscope and a test tube placed beside it - stock image
Biotechs on the Brink: 2 Stocks With Huge Potential (DRUG)
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.
Bright Minds Biosciences initiated with an Overweight at Piper Sandler
Bright Minds Biosciences Inc. stock logo
Cantor Fitzgerald Forecasts DRUG FY2025 Earnings
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will po
Bright Minds Biosciences Inc. stock logo
Bright Minds Biosciences (NASDAQ:DRUG) Earns Overweight Rating from Analysts at Piper Sandler
Piper Sandler started coverage on Bright Minds Biosciences in a research report on Thursday. They set an "overweight" rating and a $93.00 price target on the stock.
Bright Minds Biosciences initiated with a Buy at H.C. Wainwright
Bright Minds Biosciences initiated with a Buy at H.C. Wainwright
Bright Minds Biosciences Inc. stock logo
Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Cantor Fitzgerald
Cantor Fitzgerald began coverage on Bright Minds Biosciences in a research note on Friday. They set an "overweight" rating on the stock.
Get Bright Minds Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter.

DRUG Media Mentions By Week

DRUG Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

DRUG
News Sentiment

1.39

0.65

Average
Medical
News Sentiment

DRUG News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

DRUG Articles
This Week

16

2

DRUG Articles
Average Week

Get Bright Minds Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:DRUG) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners